Background And Objective: Management of young men with primary bladder neck obstruction (PBNO) and dysfunctional voiding (DV) is challenging. We systematically reviewed evidence on diagnostic strategies and treatment outcomes in men aged 18-50 yr with PBNO or DV.
Methods: We conducted a comprehensive bibliographic search on the Embase, Medline, and Cochrane Library databases in July 2024.
Key Findings And Limitations: Twenty-five publications were identified. Videourodynamics represents the standard diagnostic approach. Standard therapies for PBNO include alpha-blockers (ABs) as the first-line approach and bladder neck incision (BNI) in patients failing medical therapy. Pooled estimates of total International Prostate Symptom Score (IPSS) and maximum urinary flow rate (Q) improvements at 3 mo in patients receiving ABs are 7.0 points and 4.0 ml/s, respectively. The incidence of ejaculatory dysfunction (EjD) and failure rates range from 47% to 50% and from 23% to 52%, respectively. Corresponding figures in patients undergoing surgery are 11.2 points, 6.9 ml/s, 0-88.8%, and 11.1-13.3%, respectively. OnabotulinumtoxinA, as experimental second-line therapy in PBNO, provides 2-mo mean total IPSS and mean Q improvements of 14.1 points and 9.1 ml/s, respectively, with a 0% EjD rate. However, improvements deteriorate over time. Behavioral modifications plus biofeedback represent the only approach in patients with DV, providing symptom improvement of at least 50% in 83% of patients at 3 mo. Limits of evidence include few studies, mainly retrospective design, heterogeneous populations, small sample sizes, lack of direct comparisons, and short follow-up.
Conclusions And Clinical Implications: Diagnosis of PBNO/DV in young men requires the integration of anatomical and functional data. ABs represent the first-line approach for PBNO followed by BNI in cases of failure. Behavioral modification plus biofeedback represents the only strategy tested for DV. Given the low quality of evidence, a shared decision-making approach for diagnosis and treatment is required.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.euf.2025.01.011 | DOI Listing |
J Neurosurg Case Lessons
March 2025
Department of Neurosurgery, Stanford University Medical Center, Palo Alto, California.
Background: Gangliogliomas are low-grade gliomas typically found in the temporal lobes with a low rate of malignant transformation. In rare cases, they may be found in the spinal axis.
Observations: An 8-year-old boy presented with 2 months of neck pain and upper extremity incoordination and was found to have a cervicomedullary lesion.
Front Immunol
March 2025
Department of Pharmacology, Southern Illinois University School of Medicine, Springfield, IL, United States.
Cisplatin is a chemotherapy drug used to treat different solid tumors, including ovarian, bladder, lung, and head and neck cancers. One of its significant side effects is ototoxicity, especially when high doses are required. Cisplatin-induced ototoxicity is associated with increased cochlear cell death resulting from DNA damage, caspase activation, oxidative stress, inflammation, and glutamate excitotoxicity.
View Article and Find Full Text PDFWorld J Urol
March 2025
Department of Urology, Aster Medcity, Kochi, Kerala, India.
Purpose: To evaluate the influence of detrusor apron preservation on continence in Retzius-sparing Robotic assisted radical prostatectomy (RS-RARP).
Materials And Methods: A prospective study was carried out on patients who underwent RS-RARP at our institute from January 2019 to June 2022. We aimed to identify potential factors that could affect continence, including age, BMI, ISUP Grade Group, bladder neck sparing, fascial plane of dissection, and degree of preservation of the detrusor apron.
OTO Open
March 2025
Department of Medical Oncology Kasturba Medical College, Manipal, Manipal Academy of Higher Education Manipal Karnataka India.
Objective: To assess hearing loss in patients with cancer receiving cisplatin-based chemotherapy using high-frequency pure tone average (HFPTA), distortion product otoacoustic emissions (DPOAEs), and the speech-in-noise (SPIN) test, and to identify associated factors.
Study Design: Prospective study.
Setting: Tertiary care hospital.
Objectives: We aim to describe the ProACT implantation using flexible cystoscopic guidance and to report long-term outcomes in these patients.
Patients And Methods: This single-centre retrospective study include all men who underwent ProACT™ for SUI after RP using flexible cystoscopic guidance between 2007 and 2021. The implantation was performed via a perineal approach under general or locoregional anaesthesia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!